DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 Inhibitors PD-1 and PD-L1 Inhibitors Pipeline Landscape

2022-11-14

临床结果上市批准免疫疗法临床2期ASCO会议

PD-1 and PD-L1 inhibitors PD-L1 inhibitors clinical trial pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 inhibitors drugs, analyzes DelveInsight

LAS VEGAS, Nov. 14, 2022 /PRNewswire/ -- DelveInsight's

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Competitive Landscape – 2022

' report provides comprehensive global coverage of available, marketed, and pipeline PD-1 and PD-L1 inhibitors PD-L1 inhibitors drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PD-1 and PD-L1 inhibitors PD-L1 inhibitors competitive domain.

Key Takeaways from the PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Pipeline Report

Over

180+ PD-1 and PD-L1 inhibitors PD-L1 inhibitors companies are evaluating

200+ PD-1 and PD-L1 inhibitors PD-L1 inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the PD-1 and PD-L1 inhibitors PD-L1 inhibitors market would significantly increase market revenue.

Leading PD-1 and PD-L1 inhibitors PD-L1 inhibitors companies such as

Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, ABL bio, Macrogenics, AnaptysBio, Avacta, Regeneron Pharmaceuticals, Genor Biopharma Co. Ltd, Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., Innovent Biologics, QLSF Biotherapeutics Inc., Servier, Zai Lab, EQRx, Bright Peak Therapeutics, Compass Therapeutics, Inc., Y-Biologics, Shattuck Labs, Beijing Biocytogen, Transcenta Holding, KLUS Pharma Inc., Synermore Biologics, F-Star Therapeutics Inc., Alphamab Oncology, Betta Pharmaceuticals Co., Ltd., Bolt Biotherapeutics, Medicenna Therapeutics, Celldex Therapeutics Inc., TCR² Therapeutics, Transcenta Holding, Merus, SystImmune Inc., TG Therapeutics, Elpiscience, Numab, Janux Therapeutics, Adagene, Molecular Templates, Inc., ImmuneOncia, and others are evaluating novel PD-1 and PD-L1 inhibitors PD-L1 inhibitors drug candidates to improve the treatment landscape.

Key PD-1 and PD-L1 inhibitors PD-L1 inhibitors pipeline therapies in various stages of development include

Envafolimab, Keytruda, FAZ053, TECENTRIQ, Durvalumab, SG 12473, LP 002, HBM 9027, CA 170, Tislelizumab, Geptanolimab, and others.

October 2022,

ChemoCentryx, Inc. announced two upcoming poster presentations for CCX559, the Company's investigational, highly potent, orally administered PD-L1 checkpoint inhibitor PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held November 8-12, 2022, in Boston, MA.

October 2022, Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum-resistant ovarian cancer, as well as data from the COM701 with or without nivolumab study in patients with metastatic NSCLC, as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.

October 2022, Imjudo (tremelimumab) from

AstraZeneca Zeneca was approved in the United States in combination with Imfinzi (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.

October 2022, GSK announced positive top-line results from the PERLA phase II trial, which met its primary endpoint of objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined by blinded independent central review.

September 2022, Merck announced that KEYTRUDA, Merck's anti-PD-1 therapy, received four new approvals from Japan's Ministry of Health, Labor, and Welfare (MHLW).

July 2022, TRACON Pharmaceuticals, Inc. announced the enrollment of the 36^th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed. The interim analysis is expected to occur in the fourth quarter of this year.

January 2022, Merck announced that the European Commission had approved KEYTRUDA as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.

Request a sample and discover the recent advances in the PD-1 and PD-L1 inhibitors PD-L1 inhibitors market @

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Competitive Landscape Report

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Overview

Cancer cells have programmed cell death protein 1 (PD-1) on their surfaces. Tumors use it to evade the immune system, so blocking it allows the body to attack and kill cancer. T cells constantly scan our bodies for abnormal cells and eliminate them before they can become cancerous. Finding ways to avoid or shut down the immune system is a critical step in tumor development. PD-1 proteins interact with two ligands, Programmed death-ligand 1 (PD-L1) and Programmed death-ligand 2 (PD-L2). The CD274 gene in humans encodes PD-L1.

Some of the FDA-approved PD-1 inhibitor PD-1 inhibitor drugs include pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). These drugs effectively treat various cancers, and new cancer types are added as more research demonstrates their efficacy. PD-L1 inhibitor PD-L1 inhibitor drugs include atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi).

Find out more about PD-1 PD-1 and PD-L1 inhibitors PD-L1 inhibitors drugs @

FDA-approved PD-1 Inhibitor PD-1 Inhibitor PD-1 Inhibitor Drugs

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Pipeline Analysis: Drug Profile

Keytruda: Merck

Merck's Keytruda is a humanized monoclonal antibody that binds to the programmed cell death - 1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response.

Keytruda has been approved for advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, classical Hodgkin lymphoma, microsatellite-instability-high cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma, and advanced urothelial bladder cancer.

FAZ053: Laekna Therapeutics

Laekna Therapeutics is developing FAZ053 (anti-PD-L1), an investigational immuno-oncology treatment for patients with advanced cancers. It is a monoclonal antibody that targets the protein programmed cell death-1 ligand 1. (PD-L1). FAZ053, an anti-PD-L1 monoclonal antibody, binds to PD-L1, preventing it from binding to and activating its receptor programmed death 1 (PD-1), potentially enhancing the T-cell-mediated anti-tumor immune response and reversing T-cell inactivation. Laekna intends to begin trials on combination therapies as soon as possible to address unmet cancer needs and bring innovative, effective treatments to more cancer patients in China.

A snapshot of the PD-1 and PD-L1 Inhibitors PD-1 and PD-L1 Inhibitors Pipeline Drugs mentioned in the report:

Learn more about the emerging PD-1 and PD-L1 inhibitors PD-1 and PD-L1 inhibitors pipeline therapies @

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Clinical Trials

Scope of the PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Competitive Landscape Report

Coverage: Global

Key PD-1 and PD-L1 Inhibitors Companies: Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, ABL bio, Macrogenics, AnaptysBio, Avacta, Regeneron Pharmaceuticals, Genor Biopharma Co. Ltd, Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., Innovent Biologics, QLSF Biotherapeutics Inc., Servier, Zai Lab, EQRx, Bright Peak Therapeutics, Compass Therapeutics, Inc., Y-Biologics, Shattuck Labs, Beijing Biocytogen, Transcenta Holding, KLUS Pharma Inc., Synermore Biologics, F-Star Therapeutics Inc., Alphamab Oncology, Betta Pharmaceuticals Co., Ltd., Bolt Biotherapeutics, Medicenna Therapeutics, Celldex Therapeutics Inc., TCR² Therapeutics, Transcenta Holding, Merus, SystImmune Inc., TG Therapeutics, Elpiscience, Numab, Janux Therapeutics, Adagene, Molecular Templates, Inc., ImmuneOncia, and others

Key PD-1 and PD-L1 Inhibitors Pipeline Therapies: Envafolimab, Keytruda, FAZ053, TECENTRIQ, Durvalumab, SG 12473, LP 002, HBM 9027, CA 170, Tislelizumab, Geptanolimab, and others.

Dive deep for rich insights into PD-1 inhibitors PD-1 inhibitors in development; visit @

PD-L1 Inhibitor Drugs

Table of Contents

For further information on the PD-1 and PD-L1 inhibitors PD-L1 inhibitors pipeline therapeutics, reach out @

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors Market

Related Reports

PD-1 Resistant PD-1 Resistant Head and Neck Cancer Market

PD-1 Resistant Head PD-1 Resistant Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 resistant head and neck cancer PD-1 resistant head and neck cancer companies, including

AstraZeneca, Innate Pharma, Rakuten Medical, Boehringer Ingelheim, Alkermes, among others.

Anti-CD279 (PD-1) Antibody Pipeline

Anti-CD279 (PD-1) Antibody Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Anti-CD279 (PD-1) antibody companies, including

GlaxoSmithKline, Innovent Biologics, BeiGene, Shanghai Junshi Biosciences, among others.

PD-1 Inhibitor PD-1 Inhibitor PD-1 Inhibitor Pipeline

PD-1 Inhibitor Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor PD-1 inhibitor companies, including

Merck, Sanofi, Bristol Myers Squibb, among others.

PD-1 Non-Small Cell Lung Cancer Market

PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 non-small cell lung cancer companies, including

Wuhan University, Dalian University, MSD, Sichuan University, among others.

PD-1 PD-1 Non-Small Cell Lung Cancer Pipeline

PD-1 Non-Small Cell Lung Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 non-small cell lung cancer companies, including